Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 563-570

  Tavano, Francesca ^a   di Mola, F Francesco ^a   Latiano, Anna ^a   Palmieri, Orazio ^a   Bossa, Fabrizio ^a   Valvano, Maria Rosa ^a   Latiano, Tiziana ^a   Annese, Vito ^a,b   Andriulli, Angelo ^a   di Sebastiano, Pierluigi ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Disease activity; Disease behavior; Inflammatory bowel disease; Neuroimmune inflammation; Substance P

Indexed keywords

SUBSTANCE P;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMMUNOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEUROIMMUNOMODULATION; ROC CURVE; SEVERITY OF ILLNESS INDEX; SUBSTANCE P; TIME FACTORS; YOUNG ADULT;

EID: 84860834782     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.11.004     Document Type: Article

References (41)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 1991, 325:928-937.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
3. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997, 273:G769-G775.
4. Neunlist M., Van Landeghem L., Bourreille A., Savidge T. Neuro-glial crosstalk in inflammatory bowel disease. J Intern Med 2008, 263:577-583.
5. Gross K.J., Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:918-932.
6. Margolis K.G., Gershon M.D. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009, 25:503-511.
7. Di Sebastiano P., Fink T., di Mola F.F., Weihe E., Innocenti P., Friess H., et al. Neuroimmune appendicitis. Lancet 1999, 354:461-466.
8. Kraneveld A.D., Nijkamp F.P. Tachykinins and neuro-immune interactions in asthma. Int Immunopharmacol 2001, 1:1629-1650.
9. Nockher W.A., Renz H. Neurotrophins in allergic diseases: from neuronal growth factors to intercellular signalling molecules. J Allergy Clin Immunol 2006, 117:583-589.
10. Sebastiano P., di Mola F.F., Bockman D.E., Friess H., Büchler M.W. Chronic pancreatitis: the perspective of pain generation by neuroimmune interaction. Gut 2003, 52:907-911.
11. Di Sebastiano P., di Mola F.F., Di Febbo C., Baccante G., Porreca E., Innocenti P., et al. Expression of interleukin-8 (IL-8) and substance P in human chronic pancreatitis. Gut 2000, 47:423-428.
12. Shrikhande S.V., Friess H., di Mola F.F., Tempia-Caliera A., Conejo Garcia J.R., Zhu Z., et al. NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain 2001, 91:209-217.
13. Geboes K., Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil 1998, 10:189-202.
14. Kimura M., Masuda T., Hiwatashi N., Toyota T., Nagura H. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int 1994, 44:624-634.
15. Steinhoff M.M., Kodner I.J., DeSchryver-Kecskemeti K. Axonal degeneration/necrosis: a possible ultrastructural marker for Crohn's disease. Mod Pathol 1988, 1:182-187.
16. Dvorak A.M., Silen W. Differentiation between Crohn's disease and other inflammatory conditions by electron microscopy. Ann Surg 1985, 201:53-63.
17. O'Connor T.M., O'Connell J., O'Brien D.I., Goode T., Bredin C.P., Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004, 201:167-180.
18. Fiebich B.L., Schleicher S., Butcher R.D., Craig A., Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol 2000, 165:5606-5611.
19. Koon H.W., Zhao D., Zhan Y., Simeonidis S., Moyer M.P., Pothoulakis C. Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves protein kinase Cdelta activation. J Pharmacol Exp Ther 2005, 314:1393-1400.
20. Koch T.R., Carney J.A., Go V.L. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987, 32:369-376.
21. Bernstein C.N., Robert M.E., Eysselein V.E. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993, 88:908-913.
22. Goldin E., Karmeli F., Selinger Z., Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989, 34:754-757.
23. Renzi D., Mantellini P., Calabrò A., Panerai C., Amorosi A., Paladini I., et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Ital J Gastroenterol Hepatol 1998, 30(1):62-70.
24. Michalski C.W., Autschbach F., Selvaggi F., Shi X., Di Mola F.F., Roggo A., et al. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. Am J Surg 2007, 193:476-481.
25. Johansson M., Johansson M., Norrgard O., Forsgren S. New aspects concerning ulcerative colitis and colonic carcinoma: analysis of levels of neuropeptides, neurotrophins, and TNF alpha/TNFreceptor in plasma and mucosa in parallel with histological evaluation of the intestine. Inflamm Bowel Dis 2008, 14(10):1331-1340.
26. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24:2-6.
27. Shivananda S., Hordijk M.L., Ten Kate F.J., Probert C.S., Mayberry J.F. Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. Scand J Gastroenterol 1991, 26(2):167-173.
28. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19:5-36.
29. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
30. Harvey R.F., Bradshaw J.M. A simple index of Crohn's disease activity. Lancet 1980, 1:514.
31. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987, 317:1625-1629.
32. Kukuvitis A., Kourtis A., Papaiconomou N., Zournatzi V., Makedos G., Panidis D. Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels. Fertil Steril 2003, 80:96-98.
33. Senchaudhuri P., Mehta C.R., Patel N.R. Estimating exact p values by the method of control variates, or Monte Carlo rescue. J Am Stat Assoc 1995, 90(430):640-648.
34. Mehta C.R., Patel N.R., Senchaudhuri P. Importance sampling for estimating exact probabilities in permutational inference. J Am Stat Assoc 1988, 83(404):999-1005.
35. Westfall P.H., Young S.S. Resampling-based multiple testing: examples and methods for p value adjustment 1993, John Wiley and Sons, New York.
36. Brignola C., Lanfranchi G.A., Campieri M., Bazzocchi G., Devoto M., Boni P., et al. Importance of laboratory parameters in the evalutation of Crohn's Disease activity. J Clin Gastroenterol 1986, 8:245-248.
37. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
38. Niederau C., Backmerhoff F., Schumacher B. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997, 44:90-107.
39. Minderhoud M.I., Samsom M., Oldenburg B. What predicts mucosal inflammation in Crohn's Disease patients?. Inflamm Bowel Dis 2007, 13:1567-1572.
40. Graham M.F. Pathogenesis of intestinal strictures in Crohn's Disease-an update. Inflamm Bowel Dis 1995, 1:222-227.
41. di Mola F.F., Di Sebastiano P., Gardini A., Innocenti P., Zimmermann A., Büchler M.W., et al. Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion 2004, 69:245-253.